ETF profile for WisdomTree Biorevolution (WDNA) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
WDNA ETF Profile
| Family: |
Wisdom Tree |
| Name: |
WisdomTree BioRevolution Fund |
|
|
| Inception Date: |
3-Jun-2021 |
| Termination Date: |
|
| Investment Objective: |
The fund tracks the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index. The Fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the Index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. The Index is designed to provide exposure to equity securities of exchange-listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The Index constituents are determined by an Index committee that looks at companies focusing on the application of genetic technologies to prevent and treat disease the applications of human genetic technologies to new classes of consumer products personalized for each individual the transformation of agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding the growing global population biological re-engineering used to produce an increasing percentage of the physical inputs needed for manufacturing and/or DNA as a storage solution (collectively, BioRevolution Activities). |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Twist Bioscience Corp |
TWST |
3.8274% |
| Tempus Ai Inc |
TEM |
3.4220% |
| Eli Lilly & Co |
LLY |
3.3196% |
| Natera Inc |
NTRA |
3.0361% |
| Immunome Inc |
IMNM |
2.8270% |
| Moderna Inc |
MRNA |
2.6721% |
| Thermo Fisher Scientific Inc |
TMO |
2.4711% |
| 10X Genomics Inc-Class A |
TXG |
2.4322% |
| Stoke Therapeutics Inc |
STOK |
2.2064% |
| United Therapeutics Corp |
UTHR |
2.1669% |
|
Top 10 Holdings Weight: |
28.4% |
| Number of Holdings: |
83 |
| Shares Outstanding: |
210,000 |
| Total Net Assets: |
5,032,335 |
| NAV: |
23.90 |
| Net Expense Ratio: |
0.45% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
